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Abstract—C-reactive protein (CRP) is a much used biomarker for respiratory tract infection;
however, the inﬂuence of airway infection on the CRP level in the general population has not been
well described. The study aimed to evaluate the impact of recent symptoms of airway infection on
the CRP level and how the predictive power of other known CRP predictors is inﬂuenced by taking
respiratory symptoms into account. A total of 6,325 participants, aged 38–87 years, in the Tromsø
Study, a repeated population-based survey, were examined with questionnaires, measurements of
height and weight, spirometry, and high-sensitivity CRP analyses. The mean CRP value was 2.8-
6 mg/L, and the geometric mean was 1.51 mg/L. Geometric means above 2.0 mg/L were found in
the subgroups with the following characteristics: self-reported COPD, diabetes, recent symptoms of
airway infection, forced expiratory volume in 1 s (FEV1) <80% predicted, body mass index (BMI)
≥30, and subjects treated with inhaled or oral corticosteroids. Among the subjects who reported
recent airway infection, 10.5% had a CRP value of ≥10 mg/L, compared to 3.3% among the
remaining participants. By multivariate analysis, BMI was the strongest independent predictor of the
CRP level, followed by recent airway infection, FEV1% predicted, age, and current smoking. The
study clearly demonstrates that a report of recent symptoms of airway infection strongly predicts the
CRP level in the population. Such symptoms were shared rather equally between subgroups with
increased CRP level, and the risk of being an important confounder in epidemiological studies is
probably low. In the clinical setting, care should be taken when using the CRP level as a guide for
medical prevention of chronic diseases.
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INTRODUCTION
C-reactive protein (CRP) has, since its discovery, been
associated with airway infections. The name of the acute
phase protein originates from its link to pneumococcal
infection [1]. CRP values above 100 mg/L are frequently
found in patients hospitalized with pneumonia [2, 3], and
the biomarker is used in the monitoring of pneumonia in
intensive care units [4]. The CRP test has also been found
to be useful in diagnosing pneumonia in primary care [5,
6], although elevated values may also be found in viral
respiratory infections [7, 8], with peak levels after 3–4 days
of illness [8]. High CRP levels are also found in other acute
infections, rheumatic and inﬂammatory diseases, acute
cardiovascular events, and cancer [9–11].
When high-sensitivity methodology has been applied
in the study of CRP levels in the general population,
increased levels have been associatedwith increased risk of
cancer [12] and coronary heart disease, including myocar-
dial infarction [10]. Statin use has been found to lower both
the CRP level and the incidence of myocardial infarction,
and CRP levels down to 3 mg/L, and even 2 mg/L, have
been suggested as a support for prescribing statins [13].
Corticosteroids are also anti-inﬂammatory drugs that lower
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the CRP level [14, 15]. Estrogens have an opposite effect,
however probably by altering the metabolism of CRP [16].
Raised CRP level by increasing age has been found
in studies on the CRP level in a general population [17,
18]. This may be related to the increased morbidity of
cancer and cardiovascular diseases with increasing age,
but may also be partly explained by the impact of age-
related factors like pack-years of smoking [19] and the
prevalence of bronchial airﬂow limitation [20]. A very
strong predictor, not related to age in the adult
population, is obesity [21] or the body mass index
(BMI) [20].
The temporary increase in the CRP level due to
respiratory tract infection is a potential confounder both
when clinicians consider statin treatment based on the
CRP value and when epidemiologists study the effect of
chronic diseases and medication on the CRP level.
However, the explanatory variable of airway infections
has not been taken into account in the major population-
based studies on CRP [17, 18, 22–24], except in
NHANES [25]. The aim of our study was to describe
the inﬂuence of recent symptoms of airway infection on
the CRP value, which till now has not been well
described. We also wanted to shed light on how the
evaluation of other CRP predictors can be inﬂuenced by
taking such symptoms into account.
METHODS
Subjects
The subjects studied were participants in the Tromsø
Study, an epidemiological, prospective study of health
problems, symptoms, and chronic diseases with repeated
surveys since 1974 [26]. Tromsø is a city in the northern
part of Norway with 69,000 inhabitants. The participants
attended the sixth survey, conducted between October
2007 and December 2008. The Department of Community
Medicine, University of Tromsø, has the scientiﬁc leader-
ship and administration of the Tromsø Study.
Subjects invited to participate in Tromsø 6 included
all residents aged 40–42 or 60–87, a 10% random
sample of individuals aged 30–39, a 40% random
sample of individuals aged 43–59, and subjects who
had attended the second visit of Tromsø 4, if not already
included in the three groups above. The Population
Registry of Norway, with a unique national identity
number given to all citizens, was the source for the
invitations.
The attendance rate was 65.7%, giving 12,984
individuals attending the ﬁrst visit, which included a
questionnaire on topics such as family and social
background, lifestyle, self-rated health, previous medical
record, and use of health services, and clinical examina-
tions and anthropometric measurements. About two
thirds of the participants who attended the ﬁrst visit
were invited to a second visit with more extended
medical examination if they fulﬁlled one of the
following criteria:
Y All subjects aged 50–62 or aged 75–84
Y A 20% random sample of men and women aged 63–74
Y Subjects, if not already included in the two groups
above, who had attended the second visit of Tromsø 4.
A total of 7,958 subjects who met at the ﬁrst visit
were invited to the second visit, in which our study was
a part, and 7,307 attended (91.8%).
Examinations
Before attending the ﬁrst visit, the participants had
to ﬁll in a questionnaire on health issues including
current and previous illness, smoking habit, and use of
medication. Participants who reported “asthma” or
“chronic bronchitis/emphysema/COPD” were classiﬁed
as “asthma or COPD.” Those reporting angina pectoris,
myocardial infarction, cerebral stroke, or atrial ﬁbrilla-
tion were classiﬁed as “self-reported cardiovascular
disease.” The brand names of medicine used regularly
during the 4 weeks preceding the study were reported
and registered on the ﬁfth level of the Anatomical
Therapeutic Chemical (ATC) system, version 2007.
Participants reporting a proprietary name of a statin
(ATC group C10AA) were classiﬁed as statin users in
the analysis. Use of inhaled and systemic corticosteroids
was deﬁned from self-report of brand names belonging
to ATC groups R03BA and R03AK, and H02AB,
respectively. Participants reporting use of blood
pressure-lowering drugs were classiﬁed as users
regardless of reported brand names. Use of systemic
estrogens, (hormone therapy for menopausal symptoms,
HT) was reported by women. Height and weight were
measured during the ﬁrst visit.
At the spirometry station during the second visit, a
questionnaire concerning recent symptoms of possible
RTI was ﬁlled in including:
& Have you had any symptoms of common cold,
bronchitis, or other airway infection during the last
7 days?
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& If so, how many days have passed since the symptoms
started?
& If so, do you have such symptoms today?
This questionnaire was computerized, and each
question had to be answered before moving to the next.
Immediately after, spirometry was performed by trained
technical staff with the use of a “Sensor Medics Vmax
Encore 20” spirometer, following ATS/ERS criteria [27]
Norwegian reference values were used [28].
On the same day, blood was drawn for CRP
analysis. Sera were stored at −20°C until tested. CRP
was measured by high-sensitivity (ultrasensitive) CRP
method (particle-enhanced immunoturbidimetric assay)
in MODULAR P autoanalyzer (Roche/Hitachi) with
reagents from Roche Diagnostics GmbH, Mannheim,
Germany. The analytical sensitivity (lower detection
limit) of this assay is 0.03 mg/L, and the measuring
range is 0.1–20 mg/L. The analytical coefﬁcient of
variation (CV) is 3.6%. The samples with CRP more than
5 mg/L were analyzed by immunoturbidimetric method
with analyzer and reagents from the same manufacturer.
The analytical sensitivity (lower detection limit) of the
assay is 3 mg/L, and the analytical CV is 4.0%. Participants
with missing CRP values and those who did not answer the
questionnaire on symptoms of recent airway infection were
excluded from the statistical analysis.
Statistical Analyses
The frequency of reporting symptoms indicating
recent airway infection and the CRP value were
analyzed according to gender, age, and known predictors
of the CRP level: smoking habit, self-reported cardio-
vascular and chronic lung diseases, spirometry results,
BMI, and the use of statins, corticosteroids, and estro-
gens. Differences between groups were analyzed using
Mann–Whitney’s, Jonckhere–Terpstra, and Chi-square
tests. Because CRP values were skewed, geometric
means were calculated. The explanatory variables and
self-reported medication were entered for multivariable
linear regression analysis with log-CRP as the outcome
variable. The SPSS 16.0 for Windows (SPSS Inc.,
Chicago, IL, USA) was used in the statistical analyses.
Table 1. Characteristics of the Participants by Gender of The Tromsø Study: Tromsø 6
All, n=6,325
Women, n=3,614 Men, n=2,711
p value of gender differencen % n %
Age
<65 years 3,670 2,082 57.6 1,588 58.6 NS
≥65 years 2,655 1,532 42.4 1,123 41.4
Smoking (data missing in 88)
Current 1,147 700 19.7 447 16.7 0.001
Previous 2,910 1,446 40.7 1,464 54.6 <0.001
Never 2,180 1,408 39.6 772 28.8 <0.001
Self-reported disease
Asthma 625 408 11.6 217 8.2 <0.001
Chronic bronchitis/emphysema/COPD 327 199 5.7 128 4.9 NS
Cardiovascular disease 1,129 485 13.4 644 23.8 <0.001
Diabetes 353 180 5.1 173 6.5 0.01
Symptoms of airway infection last 7 days 783 438 12.1 345 12.7 NS
Lung function (data missing in 110)
FEV1 <80% predicted 1,328 697 19.3 670 24.7 <0.001
FEV1 ≥80% predicted 4,887 2,908 80.7 2,038 75.3
BMI (data missing in 7)
BMI <30 4,998 748 20.7 572 21.2 NS
BMI >30 1,320 2,862 79.3 2,136 78.9
Self-reported medication
Inhaled corticosteroids 353 240 6.6 113 4.2 <0.001
Oral corticosteroids 92 68 1.9 24 0.9 0.001
Antihypertensives 1,797 1,042 28.8 755 27.8 NS
Statins 1,083 551 15.2 532 19.6 <0.001
HT (estrogens) only women 317 317 8.8
NS not signiﬁcant
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A p value <0.05 was considered signiﬁcant. The Tromsø
Study complies with the Declaration of Helsinki, and
each subject gave written informed consent prior to
participation. The Regional Committee of Medical and
Health Research Ethics approved the study.
RESULTS
A total of 6,325 subjects had their CRP measured
and also answered the questions on recent airway
infection, and were thus included in the study. The
mean age was 63.6 years (range, 38–87 years), and
57.1% were women. Other characteristics and differ-
ences between the genders are shown in Table 1.
Symptoms of recent airway infection were reported in
12.4%, and with signiﬁcantly increased frequency in
current smokers, patients reporting asthma, and those
with forced expiratory volume in 1 s (FEV1) <80%
predicted (Table 2).
CRP
CRP values ranged from 0.12 to 175 mg/L, the
mean value was 2.86 mg/L, and the median value was
1.38 mg/L, whereas the geometric mean was 1.51 mg/L.
No signiﬁcant difference in geometric mean was
observed between men and women (Table 3). Geometric
means above 2.0 mg/L were found in the following
subgroups: subjects with self-reported COPD, diabetes,
or recent symptoms of airway infection, subjects with
FEV1 <80% predicted, subjects with BMI ≥30, and in
Table 2. The Frequency of Reporting Symptoms of Airway Infection 7 Days Before the Examination by Characteristics of the 6,325 Participants




Male 345 12.7 NS
Female 438 12.1
Age
<65 years 486 13.2 0.008
≥65 years 297 11.2
Smoking (data missing in 88)




Asthma 93 14.9 0.02
Chronic bronchitis/emphysema/COPD 46 14.1
Cardiovascular disease 130 11.5
Diabetes 49 13.9
Lung function (data missing in 110)
FEV1 <80% predicted 215 16.2 0.008
FEV1 ≥80% predicted 551 11.3
BMI (data missing in 7)
BMI <30 625 12.5 NS
BMI >30 158 12.0
Self-reported medication
Inhaled corticosteroids 55 15.6 NS
Oral corticosteroids 13 14.1 NS
Antihypertensives 228 12.7 NS
Statins 134 12.4 NS
HT (estrogens) 34 10.7 NS
The Tromsø Study: Tromsø 6. The p values show the statistical signiﬁcance of the difference between the displayed subgroups and between those with
and without the displayed characteristics
NS not signiﬁcant
aCurrent smokers compared with all the others
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patients treated with inhaled or oral corticosteroids
(Table 3).
CRP and Symptoms of Airway Infection
Among the subjects who reported recent airway
infection, 10.5% had a CRP value ≥10 mg/L, compared to
3.3% among the remaining subjects. A CRP value <3 mg/L
was still found in more than 50% (Fig. 1). The frequency of
having a CRP ≥10 mg/L dropped signiﬁcantly with
duration of symptoms (Table 4) from 15%, when the illness
had lasted a week or less to 3.8%when the illness had lasted
more than 3 weeks, p=0.001 (Chi-square trend). Similar
durations of symptoms were found in men and women.
Table 3. CRP Values by Characteristics of the 6,325 Participants
CRP
n Mean Geometric mean p value
All 6,325 2.9 1.5
Gender
Male 2,711 3.1 1.6 NS
Female 3,614 2.7 1.5
Age
<65 years 3,670 1.6 1.4 0.001
≥65 years 2,655 3.3 1.7
Smoking (data missing in 88)
Current 1,147 3.5 1.8 <0.001a
Previous 2,910 2.8 1.5
Never 2,180 2.6 1.4
Self-reported disease
Asthma 625 4.0 1.9 <0.001
Chronic bronchitis/emphysema/COPD 327 5.0 2.3 <0.001
Cardiovascular disease 1,129 2.9 1.6 0.003
Diabetes 353 3.7 2.1 <0.001
Symptoms of airway infection last week
Yes 783 5.1 2.3 <0.001
No 5,542 2.5 1.4
Lung function (data missing in 110)
FEV1 <80% predicted 1,328 4.0 2.1 <0.001
FEV1 ≥80% predicted 4,887 2.5 1.4
BMI (data missing in 7)
BMI <30 4,998 2.5 1.3 <0.001
BMI >30 1,320 4.0 2.4
Self-reported medication
Inhaled corticosteroids 353 5.1 2.3 <0.001
Oral corticosteroids 92 5.1 2.5 <0.001
Antihypertensives 1,797 3.2 1.8 <0.001
Statins 1,083 2.7 1.5 NS
HT (estrogens) 317 2.9 1.7 0.001
The Tromsø Study: Tromsø 6. The p values show the statistical signiﬁcance of the difference between the displayed subgroups and between those with
and without the displayed characteristics
NS not signiﬁcant
aCurrent smokers compared with all the others
Fig. 1. Distribution of CRP values according to reported/unreported
symptoms of airway infection in last week in 6,325 adults. The Tromsø
Study: Tromsø 6.
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Multivariable Analysis
By multivariable analysis, BMI was the strongest
independent predictor of the CRP level, followed by
recent airway infection, FEV1% predicted, age, and
current smoking (Table 5). BMI was a particularly
strong predictor among women, whereas symptom of
airway infection was a stronger predictor among men
than among women (Table 5). Multivariate analyses
excluding information on symptoms of airway infection
gave similar results when analyzed in all participants;
the greatest change in standardized beta was observed
for current smoking, from 0.10 to 0.12.
DISCUSSION
We have conﬁrmed the great importance of airway
infection for the CRP level in the general population. As
many as 12.4% of the subjects reported symptoms of
airway infection the week before the examination, but
Table 4. CRP Values in Subjects Reporting Symptoms of Airway Infection in the Last 7 Days, on the Examination Day (n=770), and by the
Duration of Symptoms (n=778)
CRP
n Mean Geometric mean p value
Do you have symptoms of airway infection on the examination day?
Yes 260 6.0 2.8 0.002
No 510 4.7 2.1
Duration of the symptoms
≤7 days 333 6.6 2.8 <0.001a
8–14 days 250 4.1 2.1
15–21 days 89 5.0 2.1
≥22 days 106 2.9 1.8
Table 5. Independent Predictors of Log CRP (Milligrams Per Liter) Determined by Linear Multivariate Regression, in 3,466 Women (r2 of
the Model=0.24), 2,626 Men (r2=0.17), and in both Genders (n=6,093, r2=0.20) (The Tromsø Study: Tromsø 6)
Women Men Both genders
Standardized beta p value Standardized beta p value Standardized beta p value
Subject characteristics
Male gender 0.00 NS
Age 0.12 <0.001 0.12 <0.001 0.13 <0.001
Current smoking 0.10 <0.001 0.13 <0.001 0.11 <0.001
Previous smoking 0.03 NS 0.02 NS 0.02 NS
Self-reported disease
Asthma or COPD 0.02 NS 0.02 NS 0.03 NS
Cardiovascular disease −0.02 NS −0.02 NS −0.02 NS
Diabetes 0.02 NS 0.03 NS 0.02 0.04
Recent airway infection 0.12 <0.001 0.20 <0.001 0.16 <0.001
Findings
FEV1% predicted −0.12 <0.001 −0.14 <0.001 −0.13 <0.001
BMI 0.41 <0.001 0.23 <0.001 0.34 <0.001
Self-reported medication
Inhaled corticosteroids 0.03 NS 0.02 NS 0.03 NS
Oral corticosteroids 0.05 0.001 0.01 NS 0.04 0.002
Antihypertensives 0 NS 0.4 0.03 0.02 NS
Statins −0.06 <0.001 −0.08 <0.001 −0.07 <0.001
HT (estrogens) 0.06 <0.001 0.05 <0.001
NS not signiﬁcant
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the majority of these had CRP values below 3 mg/L,
probably indicating that very mild infection or just
irritation of the airways is common. The highest CRP
values were found, as could be expected [8], when the
symptoms had lasted less than a week. The respiratory
symptoms were rather equally distributed by subgroups,
although reported signiﬁcantly more frequent in current
smokers and subjects with reduced lung function. This
explains why removing “recent airway infection”
from the multivariable analyses only moderately
changed how the CRP level was associated with the
other known predictors.
The results conﬁrm the major ﬁndings in a study
based on data from the ﬁfth Tromsø study (Tromsø 5)
[20]. Also in this earlier study, BMI, FEV1% predicted,
and current smoking were strong predictors of the CRP
value. However, low quality of the “recent airway
infection” variable was a problem in that study. Many
of the participants had answered the airway infection
question many days, and sometimes weeks, before blood
was drawn for the CRP test. The correct timing of
questions and blood sampling in the current study made
the airway infection question a much stronger predictor.
In the previous study, only subjects aged 60 years or
more were included. The wider range of ages in this
study can probably explain why age now had become a
stronger predictor in the multivariable analysis.
We did not ﬁnd any signiﬁcant association between
self-reported cardiovascular disease and the CRP value.
This is probably related to the widespread use of statins,
which was used in 49.9% of the patients in this
subgroup. This explanation implies, however, that the
prescribing of statins has probably been appropriately
directed toward persons at high risk of new cardiovas-
cular events, who could be expected to have raised CRP.
Diabetes was, on the other hand, an independent
predictor of elevated CRP in the multivariable analysis.
Statin use was reported by 40.4% of the subjects
reporting diabetes, and a weaker association with the
CRP level would probably have been the case if more
subjects in this subgroup had been treated with statins.
Our analyses conﬁrmed that the association between
BMI and CRP is stronger among women than among
men, as found by Khera and co-workers [21].
The data on airway infection are based on a
questionnaire and not on biological ﬁndings, and do
not truly reﬂect the presence of airway infections. We
are not able to explain why the association between the
CRP value and reported symptoms of airway infection
was stronger among men than among women. Could it
reﬂect a more adequate apprehension of symptoms from
the airways in men compared to women? The anyhow
high predictive power of the question, “Have you had
any symptoms of common cold, bronchitis, or other
airway infection during the last 7 days?” in the
multivariable analysis may indicate that it was well
formulated and can be used in future studies. The almost
“normal” CRP level when the symptoms had lasted
3 weeks or more may suggest that adding a question on
duration of illness may be useful.
To conclude, we have found that recent symptoms
of airway infection are a strong predictor of the CRP
level in the population. Since such symptoms were
rather equally distributed among the various subgroups
with increased CRP level in our study, the risk of being
an important confounder in epidemiological studies
seems to be low. In the clinical setting, however, care
should be taken when using the CRP level as support for
medical treatment, with, for instance, statins. A persis-
tent raised level, determined by measurements over time,
should at least have been documented.
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